Aptus Pharma Limited Share Price & Stock Analysis

Aptus Pharma Limited (BSE: 544529) is a Rajkot, Gujarat-based company in the Pharmaceutical Product Distribution industry. With a market capitalisation of ₹837 Cr, it ranks #1,678 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 13 in Pharmaceutical Product Distribution. At ₹497.00 (as of 16 Nov 2026), the share price is 2.7% below its 52-week high of ₹510.90 and 754.0% above its 52-week low of ₹58.20. The share price is up 754.0% over one year and up 92.5% over three months.

Key Metrics

Current Price₹497.00
Market Cap₹837 Cr
BSE Code544529
SectorHealth Care > Health Care Equipment and Services > Health Care Providers and Services
Sub-IndustryHealth Care Distributors > Pharmaceutical Product Distribution
P/E Ratio156.8
Return on Assets13.46%
52-Week Range₹58.20 – ₹510.90
1-Year Price Change+754.0%
3-Month Price Change+92.5%
Beta (1Y)-0.24
HeadquartersRajkot, Gujarat
Websiteaptus-pharma.com

Shareholding and Delivery

Promoters held 23.86% of Aptus Pharma Limited's shares as of Jun 2026, against 40.37% in Jun 2025 (−16.51 percentage points). Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).

About Aptus Pharma Limited

Aptus Pharma Limited engages in the marketing and distribution of finished pharmaceutical formulations. The company operates through four divisions: Aptus Pharma, Pioneer division which includes marketing of acute therapies including general anti-infectives, pain management, antacids, and gastrointestinal drugs; Aptus CD Care, Cardiac Diabetic division which includes marketing of chronic therapies, including anti-hypertensive, anti-diabetic, and lipid-lowering; Aptus Wellcare offers wellness and nutraceutical products, over-the-counter (OTC) formulations, and personal care products; and Aptus Global, export division engages in exploring and developing opportunities in overseas markets, semi-regulated and emerging countries. It also offers anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, antidiabetic, lipid-lowering, and general wellness products. Its products are available in balms,

Products and Services

1. Pharmaceuticals, Medicinal Chemicals, and Botanical Products-This segment engages in the marketing and distribution of finished pharmaceutical formulations. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Pharmaceuticals, Medicinal Chemicals, and Botanical Products-100%

Aptus Pharma Limited vs Peers — Pharmaceutical Product Distribution

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Entero Healthcare Solutions Limited₹8,733 Cr74.68.28%₹2,087 Cr+80.7%
Remus Pharmaceuticals Limited₹941 Cr26.113.78%—+0.6%
Health X Platform Limited (Sastasundar Ventures Ltd)₹871 Cr752.7-0.18%₹484 Cr-5.7%
Aptus Pharma Limited₹837 Cr156.8——+754.0%
Vasa Denticity Limited₹797 Cr76.56.68%₹87 Cr-21.4%
Bijoy Hans Ltd₹523 Cr———+128.4%
Speciality Medicines Limited₹149 Cr11.5———
Vijaypd Ceutical Limited₹136 Cr239.53%——
Royal Sense Limited₹39 Cr5.6——-71.2%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Aptus Pharma Limited?

Aptus Pharma Limited is trading at ₹497.00, with a market capitalisation of ₹837 Cr.

Which sector does Aptus Pharma Limited belong to?

Aptus Pharma Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors > Pharmaceutical Product Distribution).

What are the key financial ratios of Aptus Pharma Limited?

Aptus Pharma Limited has a P/E of 156.8.

What is the stock symbol of Aptus Pharma Limited?

Aptus Pharma Limited is listed on the BSE under the scrip code 544529.

How has Aptus Pharma Limited's share price moved over the past year?

Aptus Pharma Limited's share price is up 754.0% over one year and up 92.5% over three months. Its 52-week range is ₹58.20 to ₹510.90.

What is the promoter holding in Aptus Pharma Limited?

Promoters held 23.86% of Aptus Pharma Limited's shares as of Jun 2026, against 40.37% in Jun 2025 (−16.51 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.